EC Grant Consortium Win

Nanoscience Inc
11 April 2008

For Immediate Release



                                Nanoscience Inc.
                         ('Nanoscience' or the 'Group')


    Toumaz Technology As Part of Consortium That Wins Euro7.1 million European
                                Community Grant


Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased to
announce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'),
is part of a major collaborative research project that has been awarded a Euro7.1
million grant to fund the development of a portable blood glucose predictor
system for diabetes patients.


The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is a
unique personalised blood glucose prediction tool that allows patients at any
time to actively and accurately predict their short-term blood glucose outlook
by the analysis of data retrieved from glucose measurements, insulin delivery
data and specific patient parameters, which will be captured by non-intrusive
body-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform.


The grant award, made under the Seventh Framework Programme (FP7) of the
European Community, will fund the four-year research and development project
into the DIAdvisorTM system. The large-scale project is being coordinated by
Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a
consortium of 13 medical, industrial and academic partners, including the
European Division of the International Diabetes Federation.


Toumaz's role in the project will be to implement the DIAdvisorTM hardware and
software platform, leverage the SensiumTM intelligent data acquisition platform
and networking infrastructure to enable multiple vital signs measurements from
non-intrusive body-worn monitors to be taken and merged with manually entered '
spot' measurements (such as food intake), providing the key data for the
creation of physiological mathematical modeling, control and prediction
algorithms. The resulting analysis and prediction information will then be able
to be wirelessly transmitted to a healthcare provider advisory service, with
recommended action and treatment advice presented to the patient via a handheld
mobile device such as a Personal Digital Assistant (PDA).


First stage data gathering and clinical trials are planned to start in August
2008, with initial data expected by the end of the year.


Dr Alison Burdett, Director of Technology for Toumaz commented:


'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in the
hands of patients for the first time, empowering them in their own healthcare
management and significantly reducing the likelihood of serious complications
and recurrent hospitalisation due to poor glucose control. For healthcare
providers, DIAdvisorTM will have a significant positive impact on cost reduction
for the treatment of diabetes.'


Guy Spelman CEO of Nanoscience commented:


'This is further good news from our investment in Toumaz and its development of
the SensiumTM platform. Recognition of the growing importance of the SensiumTM
platform in more sectors in the field of medicine provides further evidence of
its versatility and increasing acceptance across global leaders and government
bodies.'


                                    - Ends -

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless
infrastructure for body monitoring solutions. Toumaz's ultra low-power smart
sensor interface and transceiver platform - the SensiumTM - enables
non-intrusive, real-time wireless monitoring of multiple vital signs for a wide
range of healthcare and lifestyle management applications.


Based on Toumaz's patented ultra-low power Advanced Mixed Signal ('AMxTM')
technology, the SensiumTM provides the enabling technology to connect the mobile
individual to healthcare providers - simply, affordably and unobtrusively.


For healthcare professionals, this transforms the possibilities for pro-active
monitoring and improved quality of care.  For patients, it delivers new
opportunities for lifestyle-compatible, personalised healthcare, as well as
better therapeutic outcomes.


Further Information:

Guy Spelman  Nanoscience Inc.   07767 338 967

Vikki Krause   Hansard Group    020 7245 1100


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAGUUQUCUPRUBG